Abstract Kirsch et al. (2008, Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5: e45), conducted a meta-analysis of data from 35 placebo controlled trials of four newer antidepressants. They concluded that while these drugs are statistically significantly superior to placebo in acute depression, the benefits are unlikely to be clinically significant. This paper has attracted much attention and debate in both academic journals and the popular media. In this critique, we argue that Kirsch et al.'s is a flawed analysis which relies upon unusual statistical techniques biased against antidepressants. We present results showing that re-analysing the same data using more appropriate methods leads to substantially different conclusions. However, we also believe that psychopharmacology has lessons to learn from the Kirsch et al. paper. We discuss issues surrounding the interpretation of clinical trials of antidepressants, including the difficulties of extrapolating from randomized controlled trials to the clinic, and the question of failed trials. We call for more research to establish the effectiveness of antidepressants in clinically relevant populations under naturalistic conditions, for example, in relapse prevention, in patients with co-morbidities, and in primary care settings.
Introduction
On 26 February 2008, PLoS Medicine published a paper by Kirsch et al. entitled 'Initial severity and antidepressant benefits' . This paper presented a meta-analysis of the data held by the US Food and Drug Administration (FDA) from 35 randomized placebo controlled trials of four newer antidepressants in the acute treatment of major depression. Kirsch et al. concluded that, while antidepressants are statistically superior to placebo, the magnitude of the drug-placebo difference is small, being on average just 1.8 points on the Hamilton depression scale (HAMD). They also reported that the drug-placebo difference is correlated with the pretreatment severity of depression.
Adopting UK National Institute for Clinical Excellence (NICE) criteria for 'clinical significance', namely, that a treatment effect is clinically significant if the benefit over placebo is at least three HAMD points or a Cohen's d effect size of 0.5 (National Institute for Clinical Excellence, 2004), they concluded that the effect of antidepressants 'reaches conventional criteria for clinical significance only for patients at the upper end of the very severely depressed category' and offered the recommendation that 'there seems little evidence to support the prescription of antidepressant medication to any but the most severely depressed patients, unless alternative treatments have failed to provide benefit'. This paper attracted much comment, including radio and front-page newspaper coverage. Kirsch et al. (2008) was still ranked amongst the most read items on the PLoS Medicine website as of March 2010, and has been accessed over 200,000 times to date. Several academic responses have since been published (Kelly, 2008; Khan and Khan, 2008; McAllisterWilliams, 2008a McAllisterWilliams, , 2008b Moller, 2008; Nutt and Malizia, 2008; Parker, 2009; Turner and Rosenthal, 2008) .
The lead author of the 2008 paper, Irving Kirsch, has previously published two other meta-analyses of antidepressant effects. The first appeared in 1998 and included 19 methodologically diverse studies of a variety of compounds, some of which are not in clinical use as antidepressants. It concluded that 'the inactive placebos produced improvement that was 75% of the effect of the active drug' (Kirsch and Sapirstein, 1998) .
The second meta-analysis, in 2002 (Kirsch et al., 2002) , utilized the FDA database of results submitted by pharmaceutical companies, and reported that for fluoxetine, nefazodone and venlafaxine, 'Approximately 80% of the response to medication was duplicated in placebo control groups, and the mean difference between drug and placebo was approximately 2 points [on the Hamilton Depression Scale]'. The 2008 paper utilized largely the same dataset as in the 2002 analysis, although it also includes data on paroxetine, data on four paroxetine trials having become available in the intervening time.
The FDA requires manufacturers to submit all available clinical trial data regarding novel drugs prior to granting licensing approval, whether or not this data is published. Kirsch et al. therefore correctly noted that their analysis was free of publication bias, a well documented problem in the antidepressant literature (Melander et al., 2003) and elsewhere in medicine.
In this review, we will argue that Kirsch et al. (2008) is a seriously flawed analysis which draws misleading conclusions on the basis of unusual and potentially biased statistical techniques. However, we also believe that psychopharmacology has something to learn from this paper, since, like depression, ostensibly learned critiques on antidepressants have a tendency to recur every few years.
Statistical issues
Commentators on Kirsch et al. have largely accepted its statistical soundness. For instance, the otherwise critical McAllister-Williams wrote: 'The meta-analysis described in this paper has been robustly carried out using standard methodology . . . Undoubtedly the findings in this analysis are robust, as far as the studies included in the analysis are concerned' (McAllister-Williams, 2008a) . This seems to us a generous evaluation.
In this section we examine, and criticize, the statistical methods used in Kirsch et al. (2008) . For further details on the issues raised in this section, readers should consult the Statistical Appendix to this paper.
Which 'drug-placebo difference'? Kirsch et al. analysed the results of 35 clinical trials, each comparing patients randomly assigned to receive an antidepressant (venlafaxine, nefazodone, paroxetine, and fluoxetine) or a pill placebo. The outcome data consists of a mean Hamilton depression rating scale score (HAMD or HRSD) before treatment, and a mean score after treatment, for each group, in each trial. Hence there are 35 Â 2 ¼ 70 before-after pairs of HAMD scores and, correspondingly, 70 pre-post change scores.
For any given trial, the benefit of antidepressants over placebo is the difference in the change (improvement) scores between the two groups. Determining the mean benefit of antidepressants would therefore seem to be a simple matter of calculating the appropriately weighted mean of the between-group differences in the 35 trials. This mean is an estimate of average benefit an individual patient can expect to experience if they are given an antidepressant, relative to a patient from the same population randomized to receive a placebo, which is a number of clear clinical relevance.
However, Kirsch et al. did not perform such an analysis. Instead, they pooled the data for all of the antidepressanttreated subjects across the 35 trials, and likewise pooled the data for all placebo-treated subjects. They then averaged the improvement scores seen in the placebo subjects and, separately, the improvement seen in the drug subjects. Finally, they compared the two averages. This is the basis of their famous result that '. . . weighted mean improvement was 9.60 points on the HRSD in the drug groups and 7.80 in the placebo groups, yielding a mean drug-placebo difference of 1.80', and this was also the basis for the two main graphs in the 2008 paper. This is a somewhat curious approach. Standard meta-analytic practice is to consider the difference in improvement between the drug group and the placebo group within each trial, and only then to average these difference values across trials. Re-analysing the data in this appropriate way, we find an overall weighted mean difference between the two groups of 2.70 (95% confidence interval (CI) 1.95, 3.44) HAMD points; rather higher than Kirsch et al.'s 1.80 . Why the discrepancy?
Firstly, the decision by Kirsch et al. to calculate the mean drug and mean placebo improvement scores and then take the difference between them introduces bias. This approach effectively treats each trial as being two entirely separate experiments, one measuring improvement on placebo, the other measuring improvement on drug. It also assumes that the placebo improvement is the same across all trials, yet it is because the placebo response in any given trial cannot be determined beforehand that randomized controlled trials (RCTs) are conducted.
Kirsch et al.'s method is effectively blind to an important element of the information provided by the 35 trials, namely the pairing between the drug group and the placebo group in each trial. Although this approach was used previously by Kirsch and Sapirstein in their original 1998 antidepressant meta-analysis, they at least acknowledged its novel nature in that paper (Kirsch and Sapirstein, 1998) . In the 2008 paper, Kirsch et al. did not discuss or defend their choice of method.
Secondly, Kirsch et al.'s use of fixed-effect precisionweighting to weight each trial also introduces bias. A fundamental assumption of fixed-effects analysis is that the magnitude of the effect being estimated is identical across trials. In fact, the magnitude of the antidepressant effect could vary between trials for numerous reasons, e.g. due to the use of different antidepressants or different patient populations. Indeed, one of Kirsch et al.'s claims is that the effects of antidepressants vary with differing average initial severity, Therefore, it is appropriate to use random-effects weighting, which does not assume that effects are constant across trials, in this case. Random-effects weighting places more weight on smaller studies, which is a weakness whenever publication bias leads to over-representation of small, positive studies. However, we do not believe this is the case here, since this data-set is known to be free of publication bias as it is based on results submitted to regulatory authorities, including unpublished data.
Indeed, it could be said that Kirsch et al.' s methodology is in fact more biased than the publication bias that they avoided. As stated above, our estimated mean drug-placebo difference, using a precision weighted random effects model, including unpublished data, is 2.70 HAMD points. Excluding those trials which were not published in full gives a result of 3.37 points. Thus, publication bias would have inflated the apparent effect by around 0.67 points. However, Kirsch et al.'s methodology produced a figure of 1.80, thus underestimating the effect by 0.90 points.
The non-standard use of standardized scores
In addition to the analysis using HAMD scores, discussed above, Kirsch et al. also present an analysis using a standardized measure of effect size, Cohen's d. Cohen's d is the mean of the difference between two groups of scores, divided by the standard deviation of that difference (Cohen, 1988) . In this case, d was calculated, for drug and placebo groups separately, using the change in HAMD scores from the beginning to the end of the trial. Kirsch et al.'s overall estimate of the drug vs. placebo difference was d ¼ 0.32.
In meta-analysis, converting results to d scores is useful when the trials of interest did not all share a common outcome measure, as it allows the relative magnitude of treatment effects to be compared, because d is a unitless number. In this case, however, all of the trials used the same scale to rate depression, and it is therefore appropriate to use the HAMD scores only, as the Cochrane handbook of meta-analysis states (The Cochrane Collaboration, 2008: Section 9.2.3). One advantage to doing so is that the mean HAMD difference is directly interpretable, while the standardized mean difference (d score) is a statistical construct.
Kirsch et al. did perform an analysis using raw HAMD scores, in addition to the one using d scores, but they do not mention that some of their most interesting results are only apparent if the d scores are used.
The most notable example is the statement that:
'. . . Although differences in improvement increased at higher levels of initial depression, there was a negative relation between severity and the placebo response, whereas there was no difference between those with relatively low and relatively high initial depression in their response to drug. Thus, the increased benefit for extremely depressed patients seems attributable to a decrease in responsiveness to placebo, rather than an increase in responsiveness to medication.' In one form or another, this claim appears three times in the Discussion section, as well as in the Abstract, and in the Editor's Summary of the paper. But it only holds true when the (inappropriate) standardized mean difference (d) analysis is used (Figure 1 ). If the raw mean difference score is used instead, this effect vanishes: while the finding of increasing drug-placebo difference with higher baseline severity remains, this is seen to be driven by increasing improvement in the drug group, and essentially constant improvement in the placebo group (Figure 2 ).
Using raw HAMD scores is more usual, and there is no reason to prefer the standardized mean difference (d) in this case. Previous meta-analyses have also found higher antidepressant improvements with increasing severity: see, for example, Khan et al. (2002) , although unlike Kirsch et al. these authors rightly acknowledged that their data 'cannot be directly applied to clinical practice. Research These fixed effects regression lines (weighted by sample size) produce a threshold around a baseline HAMD score of 26 points (precision weighted random and fixed effects regression lines are very similar). The placebo regression line slope is not statistically significantly different from zero; in other words, there is no decline in the magnitude of the placebo response in trials with higher mean baseline severity values. Note that the remarks in the section Which 'drug-placebo difference'? of this paper also apply to this analysis. Figure 3 from Kirsch et al. (2008) showing the standardized mean difference (d) score for improvement on drug and placebo in relation to baseline HAMD score.
participants meet stringent exclusion and inclusion criteria and are not representative of the general population of patients with depression. ' Kirsch et al. also state that the NICE threshold for clinical significance, d > 0.5, is reached only with a baseline HAMD of about 28. However, the other criterion specified by NICE, a mean difference of greater than 3 HAMD points, is reached at a lower baseline severity of approximately 26, as can be seen in Kirsch et al.'s Figure 4 . Both criteria are equally arbitrary, but it is curious that Kirsch et al. quoted only the one which led to conclusions less favourable to antidepressants, and although the difference between 28 and 26 is perhaps modest, it brings the 'clinical significance' threshold close to the average baseline severity of the studies, since the median weighted mean baseline score is 25.5.
Rating depression and rating antidepressants
We have criticized Kirsch et al.'s (2008) analysis for using non-standard, inappropriate and biased methods. However, even adopting standard meta-analytic statistics, we find an overall weighted average of just 2.7 points, on a scale with a maximum score of 52 (see Table 1 ). Although this might appear small, interpretation of the magnitude of the effect depends upon the assumptions we make about the nature of antidepressant clinical trials.
Better drugs or worse placebos? Kirsch et al. contend that for the four antidepressants they consider, 'efficacy reaches clinical significance only in trials involving the most extremely depressed patients, and that this pattern is due to a decrease in the response to placebo rather than an increase in the response to medication'.
There are several problems with this statement. Firstly, as noted above, this finding is not robust because it is only apparent when standardized effect scores are used. Secondly, it makes no sense to say that the increasing efficacy of antidepressants in more severe depression is not due to an increase in the response to medication, but is on the contrary due to decreasing response to placebo. The pharmacological effects of any medication are defined as (improvement with medication -improvement with placebo).
Unfortunately, many commentators made misleading statements to the effect that even in severe depression, antidepressants were somehow not 'really' effective at all, because the apparent effect was driven by worse placebo effects. Not even the Editor's Summary in PLoS Medicine avoided such confusion: 'Additional analyses indicated that the apparent clinical effectiveness of the antidepressants among these most severely depressed patients reflected a decreased responsiveness to placebo rather than an increased responsiveness to antidepressants.' Nothing in the data suggests that the clinical effectiveness is merely 'apparent'.
What is 'very severe'? Kirsch et al. state that: 'the differences between drug and placebo were not clinically significant in clinical trials involving either moderately or very severely depressed patients, but did reach the criterion for trials involving patients whose mean initial depression scores were at the upper end of the very severe depression category (mean HRSD baseline approx. 28).' This is consistent with the terminology proposed by the American Psychiatric Association (American Psychiatric Association, 2000) and adopted by NICE (National Institute for Clinical Excellence, 2004): 'Moderate' 14-18, 'Severe' 19-22, and 'Very Severe' 23þ. However, this scheme is arbitrary, and many commentators have argued that it overstates the severity of any given point on the Hamilton scale, e.g. Moncrieff and Kirsch (2005) , who said that '''severe'' depression [by these APA criteria, i.e. HAMD 19-22] . . . would generally be referred to as moderately depressed'.
Moreover, Kirsch et al. neither looked for, nor found, a correlation between depression severity and response to antidepressants at the level of individual patients. Rather, they found a correlation between mean depression severity amongst recruits to trials and reported effect size within such trials. It is entirely plausible that trials recruiting more severe patients tend to have other characteristics which lead to their finding larger drug-placebo differences. Furthermore, the included trials only comprise a relatively narrow range of HAMD scores, the great majority being between 23 and 28, i.e. within the 'very severe' range, as defined by the APA. Therefore, Kirsch et al.'s claim that 'there seems little evidence to support the prescription of antidepressant medication to any but the most severely depressed patients, unless alternative treatments have failed to provide benefit', is a double extrapolation. It extrapolates from data on trials to data on patients, and it extrapolates from a regression line based on data from 'very severely' depressed patients to other patients. Thus, while this statement may be strictly accurate in terms of the data-set analysed in Kirsch et al. (2008) , it is equally true that there is little evidence in this data-set that antidepressants are ineffective in mild depression, because only one of the trials included was about patients with mild depression. Other results from beyond the FDA approval dataset are more relevant to this issue (Lima and Moncrieff, 2000) .
Are all drugs equal?
Kirsch et al. pooled data on four different antidepressants: the SSRIs paroxetine and fluoxetine, the 5HT antagonist and weak SSRI nefazodone, and the SNRI venlafaxine. Combining such diverse drugs together seems curious: venlafaxine is widely regarded as more effective than SSRIs, at least in some patients (Nemeroff et al., 2008) , whereas nefazodone is no longer widely used having been withdrawn from the market in Europe and the USA. Kirsch et al. conclude that their data show the four drugs to be equally effective. However, using our analysis we find overall effects vs. placebo for nefazodone, fluoxetine, paroxetine and venlafaxine to be 1.65, 2.06, 3.38 and 3.54 Hamilton points, respectively.
In other words, venlafaxine and paroxetine had larger effect sizes than fluoxetine or nefazodone -venlafaxine's being more than twice nefazodone's -and the overall effect sizes of these two drugs were larger than the three-HAMD-point clinical effectiveness threshold defined by NICE. Kirsch et al. say that the differences between drugs are accounted for by differences in the baseline severity of patients in the relevant trials, but regressing against baseline severity we find estimated effects of 2.52, 2.96, 3.24 and 3.96 at a baseline HAMD of 26.
These figures are not statistically significantly different from one another, so it is not possible to conclude from this data that (for example) venlafaxine is more effective than other antidepressants, but it is equally impossible to draw the opposite conclusion, especially since these trials were not designed, or powered, to address this. This is something that can only be resolved by head-to-head trials. For a recent synthesis of the results of such trials, finding some drugs to be significantly more effective than others, see Cipriani et al. (2009) , although see also Ioannidis (2009) .
What is being measured?
Perhaps the most overlooked aspect of the data included in Kirsch et al. (2008) is that it is not about the effects of antidepressants upon depression, but rather about the effects of antidepressants on the HAMD.
For research purposes, it is often necessary to attempt to quantify the severity of depression, but there is no such thing as a 'measure' of depression in the same way as a measure of weight or temperature. As any clinician and any patient with experience of the illness will be able to attest, estimating the severity of depression can be a difficult task in itself.
The HAMD has been the most popular rating scale for use in antidepressant trials for almost 50 years. However, it has long been argued that it is far from ideal in this role. For example, the authors of one recent review noted numerous problems with the HAMD including its multidimensional structure, the fact that it describes a construct of depression which corresponds poorly to that found in DSM-IV (e.g. it does not measure feelings of worthless or hopelessness, or anhedonia except indirectly), and that several items have poor reliability (Bagby et al., 2004) .
Furthermore, writing in the British Medical Journal, Moncrieff and Kirsch observed of the Hamilton scale that it has:
'a maximum score of 52 and contains seven items concerning sleep and anxiety, with each item on sleep scoring up to 6 points. Hence any drug with some sedative properties, including many antidepressants, could produce a difference of 2 points or more without exerting any specific antidepressant effect' (Moncrieff and Kirsch, 2005) .
Although wrong in point of fact (the HAMD contains three sleep items, for early, middle, and late insomnia, with a maximum score of 2 each, or 6 in total, not 6 each), the argument is a valid one (see also Kirsch, 2008) . A change in total HAMD score does not necessarily imply a change in mood.
However, this argument remains valid if it is turned on its head: a lack of change, or a small change, in total rating scale score does not imply a lack of change, or a small change, in the severity of depressed mood. For example, were a certain drug to improve mood and reduce suicidality, but also cause insomnia and reduce appetite, it might have no effect on total HAMD score, or might even increase it.
These considerations are theoretical. Fortunately, there is empirical data to draw on. Ten years ago Faries et al. directly tested, and rejected, the idea that the ability of antidepressants to lower HAMD scores is driven by 'non-specific' effects such as improving sleep or appetite. They found that the average drug-placebo effect size across eight trials of fluoxetine in depression was d ¼ 0.45 using the Maier and Philipp subscale, as opposed to d ¼ 0.37 with the full scale HAMD. The Maier and Philipp subscale of the HAMD consists of six Hamilton items: mood, feelings of guilt, impairment to work and activities, observed retardation, observed agitation, and psychic anxiety (Maier and Philipp, 1985) . Thus the effect size of fluoxetine was increased by 22% by considering only those items which rate core depressive symptoms (Faries et al., 2000) .
Faries et al. also examined each individual Hamilton scale item, and found that, across several trials of tricyclic antidepressants, the six items which showed the largest drug-placebo effect sizes were: feelings of guilt, early insomnia, mood, suicide, impairment to work and activities, and psychic anxiety. All are core symptoms of clinical depression. A recent analysis of two large paroxetine trials (Santen et al., 2008) came to a very similar conclusion.
The best evidence is therefore that antidepressants improve depression rating scale scores by treating depression. However, the size of the measured effect of antidepressants against placebo is determined by the rating scale used (Bech, 2009) . By implication, even more sensitive rating scales could provide even higher effect sizes. It might be complained that it is circular logic to favour a rating scale merely because it discriminates between antidepressants and placebos, and then to use it to claim that antidepressants work well! But while the original Hamilton scale was simply the invention of Max Hamilton, HAMD subscales such as the Maier and Philipp, the Bech-Rafaelson Melancholia Scale, and others, were developed following quantitative analysis of HAMD data and are superior on psychometric measures (Moller, 2001) . They could therefore be called rather more 'evidence based'.
How small is 'small', or: what is 80% of an emotion?
We believe that it is problematic to describe any given HAMD difference as 'small' or 'large' in terms of clinically meaningful effects. Although NICE have called a difference of less than three HAMD points clinically insignificant, this is an arbitrary criterion, as Moncrieff and Kirsch noted (Moncrieff and Kirsch, 2005) . Although our point estimate of the overall effect size was just below this threshold (2.70), the 95% CIs cannot exclude an effect of this magnitude (95% CI 1.95-3.44).
We also question the validity of statements such as 'The response to placebo in these trials was exceptionally large, duplicating more than 80% of the improvement observed in the drug groups'. The placebo groups may have shown around 80% of the HAMD change seen in the drug groups, but only under a number of assumptions can this be taken to mean that they experienced 80% of the clinical improvement. For example, this requires that every point of decrease on the HAMD corresponds to a certain constant degree of clinical improvement.
This seems implausible, especially considering the heterogeneous nature of the Hamilton items -a decrease on the Suicide item is surely more clinically significant than a decrease on Middle Insomnia. In mathematical terms, Kirsch et al. are treating the HAMD as an interval scale, in which a certain numerical difference in score corresponds to a certain difference in the phenomenon being measured, but the HAMD is in fact an ordinal scale, in which a higher score corresponds to a greater severity, but not necessarily to any given degree of greater severity.
A more fundamental point is that Kirsch et al.'s statement assumes that the HAMD change recorded in the placebo group represents real improvement. Yet in fact it includes many other factors, such as demand effects (in this case, a tendency for patients to act in ways which conform to the experimenter's expectation of improvement (Nichols and Maner, 2008) ), regression to the mean, the impact of initial rating score inflation, and other such artefacts.
The design of a randomized controlled trial ensures that these effects are equally present in both the drug and the placebo group. Therefore the difference between the two groups does represent real improvement, but the improvement seen in the placebo group cannot be assumed to be such. A fortiori, the improvement in the placebo group cannot be read as a 'placebo effect' that would be seen in actual clinical practice.
In summary, existing placebo controlled trials of antidepressants are neither designed to measure, nor be capable of measuring, the absolute magnitude of either placebo or drug effects. Rather, appropriately powered clinical trials are useful as a means of confirming, or not confirming, the antidepressant efficacy of a given treatment, or of showing one treatment to be superior or equivalent to another.
Lessons for psychopharmacology

Further remarks on antidepressant trials
In this article, we have argued that the Kirsch et al. (2008) analysis is seriously flawed. A number of other commentators, e.g. (Bech, 2009; Broich, 2009; Hegerl and Mergl, 2010; Khan and Khan, 2008; Mathew and Charney, 2009; McAllisterWilliams, 2008a; Moller, 2008; Nutt and Malizia, 2008; Parker, 2009; Turner and Rosenthal, 2008) have also criticized the Kirsch et al. (2008) paper. The main arguments advanced by one or more of these commentators include:
. The observation that the conclusion that antidepressants are of no clinical significance in most patients does not accord with psychiatrists' clinical experience. . Criticism of Kirsch et al.'s attribution of the increasing drug-placebo difference with higher baseline scores to declining placebo effects, rather than to increasing pharmacological effects (see Better drugs or worse placebos? above). Note that, unlike previous commentators, we argue that this attribution is not only confused but also statistically flawed (see The non-standard use of standardized scores above). . The argument that Kirsch et al.'s analysis included only short-term efficacy trials (typically six weeks' duration, sometimes as short as four weeks) and that data on longer-term relapse prevention with antidepressants has found large positive effects (Geddes et al., 2003) . There is no reason to think that all of the benefits of antidepressants manifest themselves by six weeks in clinical practice. . Criticism of the statement that 'only the most severely depressed patients' benefit from antidepressants. Because only two of the included trials were in in-patients, and patients with suicidality or co-morbid mental health problems are routinely excluded from antidepressant trials for ethical reasons, the trials analysed by Kirsch et al. did not sample patients who would be considered severely depressed in a clinical sense. . The argument that many modern antidepressant trials, including those included in the analysis, utilize problematic methods of recruitment. Commonly criticized practices include finding volunteers through community advertisement, rather than by clinical referral; excluding patients with suicidal thoughts or actions; and excluding patients with co-morbid substance abuse, anxiety or personality disorders. The result, it's argued, is that many of the patients included in modern trials are not representative of patients in the clinic and may not even be clinically depressed in the usual sense. The fact that mean baseline HAMD scores are relatively high (as high as was the case 20 years ago (Walsh et al., 2002) ) is ascribed to the conscious or unconscious 'inflation' of baseline HAMD scores by raters eager to recruit participants. . The argument that the high frequency of contact with researchers experienced by patients in clinical trials could have a real or apparent therapeutic effect, at least for the duration of the study, which would not be seen in the clinic. Also, many antidepressant trials allow the use of concomitant medications such as hypnotics, which will have a beneficial effect.
. The argument that when the outcomes of antidepressant trials are expressed as categorical figures, such as the percentage of patients meeting some defined criteria for remission, as opposed to continuous numbers (such as HAMD change scores), drug-placebo differences appear larger. However, it should noted that Kirsch and Moncrieff have criticized this apparent superiority of categorical outcome data as an 'illusion' (Kirsch and Moncrieff, 2007) .
As those familiar with the literature will know, concern has long been growing over the fact that trials of antidepressants often 'fail'. Many points have been made in an attempt to explain this phenomenon and such arguments largely overlap with those listed above; for a discussion see Montgomery (1999) .
In the light of such arguments, we believe that it is impossible to draw any conclusions about the clinical significance of the pharmacological effects of antidepressants from shortterm efficacy trials. Although the results of such trials are of interest to authorities concerned with licensing drugs as safe and effective, including the FDA, the UK's MHRA and the EU's EMEA, they are probably insufficient for agencies concerned with assessing clinical and cost effectiveness, such as NICE.
We therefore argue that the conclusions of Kirsch et al. (2008) regarding the (lack of) clinical effectiveness of antidepressants are not supported, even setting aside the statistical concerns raised in the first part of this paper.
Trials -what are they good for?
Commentators writing in the British Journal of Psychiatry seven years ago, following the publication of a very similar meta-analysis (Kirsch et al., 2002) , said, 'we simply do not know how big the effect of antidepressants is in clinical practice because RCTs are not designed to tell us this' (Parker et al., 2003) . This remains true.
Some may find this conclusion a comforting one, compared with the view that antidepressants have a very small effect in practice, but it is clearly an unsatisfactory state of affairs. Doctors, patients and policy-makers need to be able to make evidence-based decisions about the utility of antidepressants, some of the most prescribed medications in the world. At present we do not believe that this is possible in many cases, leaving psychopharmacology to rely upon clinical experience, rather than evidence, to judge how well antidepressants work in practice, as opposed to if they work, although it should be noted that this is not a problem with antidepressants alone and that the state of the evidence on psychological treatments for depression has been deemed even worse (Nutt and Sharpe, 2008) .
So long as the evidence base on antidepressants remains so limited in scope, it seems likely that challenges such as those of Kirsch et al. will continue, with negative effects on public attitudes towards these drugs. Appeals to clinical experience, while they may be valid, are increasingly greeted with scepticism in an era of evidence-based medicine. Improving the quality and the quantity of research on existing antidepressants could therefore be more important to psychiatry than the development of new drugs.
Echoing others (Parker, 2009) , we therefore call for more research on the clinical effectiveness of antidepressants in naturalistic settings, for example, in relapse prevention, in patients with psychiatric co-morbidities, and in primary care. We also recommend the development and use of evidence-based alternatives to the Hamilton depression scale.
The true lesson of the present controversies may be not that antidepressants do not work very well, but that antidepressant research does not work very well. Practically, the implication is not that we should be prescribing antidepressants less, but rather we should be studying them more -and better. If Kirsch et al. (2008) serves to prompt such research, then this much-maligned paper may turn out to be a valuable contribution to modern psychiatry.
Statistical Appendix Introduction
Raw data can be found in Table SA1 . The data consists of 35 RCTs, each with a drug and a placebo group. The data is derived from Table 1 in Kirsch et. al. (2008) . For each group, the figures available consist of mean baseline and post-treatment HAMD scores, mean change in HAMD score, and the Cohen's effect size (d) of the change score.
The standard deviation of the change scores (SDc) are not explicitly presented in Kirsch et al.'s 
Reproducing Kirsch et al.'s results
We believe that Kirsch et al. derived their results, most notably an overall drug-placebo difference of 1.8 HAMD points, by calculating the precision-weighted (i.e. weighting by N/(SDc 2 )) mean of the change scores for all of the antidepressant-treated subjects and all of the placebo-treated subjects, and then calculating the difference between these two scores. Table SA1 shows that we were able to derive the 1.8 figure (1.78) from the data by performing this analysis, thereby reproducing Kirsch et al.'s results (G46).
Critique
We believe that this approach is flawed for a number of reasons. See our paper for details. We also argue that there are other problems with additional analyses presented in Kirsch et al. (2008) . We provide the results of our own reanalyses of the same data in our paper.
In the meta-analysis, precision weighted analyses (fixed and random effects) were performed in RevMan 5.0 1 . Sample size weighted analyses were performed in Open Office Calc 2 , weighting by the harmonic mean of the placebo and drug sample sizes. We also performed the same analyses using STATA 9 3 . In the meta-regression, precision and sample size weighted analyses were performed in SPSS 4 using macros by DB Wilson 5 . 
